Other languages Talphera, Inc.

Equities

TLPH

US00444T2096

Market Closed - Nasdaq Other stock markets 01:30:00 02/05/2024 am IST			5-day change	1st Jan Change
1 ^USD	-2.91%		+3.09%	+36.05%

06/03	Talphera, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
06/03	Transcript : Talphera, Inc., Q4 2023 Earnings Call, Mar 06, 2024

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Talphera, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03
Talphera, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	07/03
Talphera, Inc. Announces Management Changes	01/03
Talphera, Inc. Appoints Abhinav Jain to Serve as a Class II Director	23/01
XOMA Acquires Interest in Pain Management Medication Dsuvia for $8 Million	18/01
XOMA Corporation acquired DSUVIA® of Talphera, Inc. for $8 million.	18/01
AcelRx Pharmaceuticals, Inc. will Change its Ticker to TLPH from ACRX	10/01
Talphera Expects to Initiate the Registrational Study of Niyad	09/01
AcelRx Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2023	09/11
AcelRx Pharmaceuticals, Inc. Receives IDE Approval for Niyad and Advances to A Single Registration Study	03/23/03
AcelRx Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/23/11
AcelRx Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	11/23/11
Vertical Pharmaceuticals, LLC acquired DSUVIA from AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) for $119.2 million.	03/23/03
AcelRx Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	31/23/31
AcelRx Pharmaceuticals Q4 Loss Narrows After Sales Jump	31/23/31
AcelRx Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	31/23/31
AcelRx Selling Dsuvia to Alora Pharmaceuticals; Shares Rise	14/23/14
AcelRx Pharmaceuticals, Inc. Announces Peer-Reviewed Publication on the Use of Dsuvia(R) for in Office Rhinology Procedures	01/23/01
AcelRx Pharmaceuticals to Raise $7.5 Million via Securities Offering	27/22/27
AcelRx Says Study of Sufentanil Sublingual Tablets for Surgical Pain Management Shows Better Results Than Standard Therapy	09/22/09

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Talphera, Inc.

Equities

TLPH

US00444T2096

Other languages

Filters